These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 19295615)

  • 1. N-propionyl-cysteaminylphenol-magnetite conjugate (NPrCAP/M) is a nanoparticle for the targeted growth suppression of melanoma cells.
    Sato M; Yamashita T; Ohkura M; Osai Y; Sato A; Takada T; Matsusaka H; Ono I; Tamura Y; Sato N; Sasaki Y; Ito A; Honda H; Wakamatsu K; Ito S; Jimbow K
    J Invest Dermatol; 2009 Sep; 129(9):2233-41. PubMed ID: 19295615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of putative neo-antigen formation from N-propionyl-4-S-cysteaminylphenol, a tyrosinase substrate, in melanoma models.
    Ito S; Nishigaki A; Ishii-Osai Y; Ojika M; Wakamatsu K; Yamashita T; Tamura Y; Ito A; Honda H; Nakayama E; Jimbow K
    Biochem Pharmacol; 2012 Sep; 84(5):646-53. PubMed ID: 22728921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth inhibition of re-challenge B16 melanoma transplant by conjugates of melanogenesis substrate and magnetite nanoparticles as the basis for developing melanoma-targeted chemo-thermo-immunotherapy.
    Takada T; Yamashita T; Sato M; Sato A; Ono I; Tamura Y; Sato N; Miyamoto A; Ito A; Honda H; Wakamatsu K; Ito S; Jimbow K
    J Biomed Biotechnol; 2009; 2009():457936. PubMed ID: 19830247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanoma-targeted chemo-thermo-immuno (CTI)-therapy using N-propionyl-4-S-cysteaminylphenol-magnetite nanoparticles elicits CTL response via heat shock protein-peptide complex release.
    Sato A; Tamura Y; Sato N; Yamashita T; Takada T; Sato M; Osai Y; Okura M; Ono I; Ito A; Honda H; Wakamatsu K; Ito S; Jimbow K
    Cancer Sci; 2010 Sep; 101(9):1939-46. PubMed ID: 20594194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-propionyl-4-S-cysteaminylphenol induces apoptosis in B16F1 cells and mediates tumor-specific T-cell immune responses in a mouse melanoma model.
    Ishii-Osai Y; Yamashita T; Tamura Y; Sato N; Ito A; Honda H; Wakamatsu K; Ito S; Nakayama E; Okura M; Jimbow K
    J Dermatol Sci; 2012 Jul; 67(1):51-60. PubMed ID: 22622238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cell receptor repertoires of tumor-infiltrating lymphocytes after hyperthermia using functionalized magnetite nanoparticles.
    Ito A; Yamaguchi M; Okamoto N; Sanematsu Y; Kawabe Y; Wakamatsu K; Ito S; Honda H; Kobayashi T; Nakayama E; Tamura Y; Okura M; Yamashita T; Jimbow K; Kamihira M
    Nanomedicine (Lond); 2013 Jun; 8(6):891-902. PubMed ID: 23066648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective incorporation and specific cytocidal effect as the cellular basis for the antimelanoma action of sulphur containing tyrosine analogs.
    Thomas PD; Kishi H; Cao H; Ota M; Yamashita T; Singh S; Jimbow K
    J Invest Dermatol; 1999 Dec; 113(6):928-34. PubMed ID: 10594732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanoma-Targeted Chemothermotherapy and In Situ Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite Nanoparticles.
    Jimbow K; Ishii-Osai Y; Ito S; Tamura Y; Ito A; Yoneta A; Kamiya T; Yamashita T; Honda H; Wakamatsu K; Murase K; Nohara S; Nakayama E; Hasegawa T; Yamamoto I; Kobayashi T
    J Skin Cancer; 2013; 2013():742925. PubMed ID: 23533767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4-S-Cysteaminylphenol-loaded magnetite cationic liposomes for combination therapy of hyperthermia with chemotherapy against malignant melanoma.
    Ito A; Fujioka M; Yoshida T; Wakamatsu K; Ito S; Yamashita T; Jimbow K; Honda H
    Cancer Sci; 2007 Mar; 98(3):424-30. PubMed ID: 17270032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulation of Melanoma by Chemo-Thermo-Immunotherapy Using Conjugates of Melanogenesis Substrate NPrCAP and Magnetite Nanoparticles: A Review.
    Tamura Y; Ito A; Wakamatsu K; Kamiya T; Torigoe T; Honda H; Yamashita T; Uhara H; Ito S; Jimbow K
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and antitumour effect of the melanogenesis-based antimelanoma agent N-propionyl-4-S-cysteaminylphenol.
    Tandon M; Thomas PD; Shokravi M; Singh S; Samra S; Chang D; Jimbow K
    Biochem Pharmacol; 1998 Jun; 55(12):2023-9. PubMed ID: 9714323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of in vitro cytotoxicity of N-acetyl and N-propionyl derivatives of phenolic thioether amines in melanoma and neuroblastoma cells and the relationship to tyrosinase and tyrosine hydroxylase enzyme activity.
    Gili A; Thomas PD; Ota M; Jimbow K
    Melanoma Res; 2000 Feb; 10(1):9-15. PubMed ID: 10711635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer effect and immune induction by hyperthermia of malignant melanoma using magnetite cationic liposomes.
    Suzuki M; Shinkai M; Honda H; Kobayashi T
    Melanoma Res; 2003 Apr; 13(2):129-35. PubMed ID: 12690295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sulfur containing tyrosine analogs can cause selective melanocytotoxicity involving tyrosinase-mediated apoptosis.
    Minamitsuji Y; Toyofuku K; Sugiyama S; Yamada K; Jimbow K
    J Investig Dermatol Symp Proc; 1999 Sep; 4(2):130-6. PubMed ID: 10536987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoclusters of crystallographically aligned nanoparticles for magnetic thermotherapy: aqueous ferrofluid, agarose phantoms and ex vivo melanoma tumour assessment.
    Coral DF; Soto PA; Blank V; Veiga A; Spinelli E; Gonzalez S; Saracco GP; Bab MA; Muraca D; Setton-Avruj PC; Roig A; Roguin L; Fernández van Raap MB
    Nanoscale; 2018 Dec; 10(45):21262-21274. PubMed ID: 30418464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A/C magnetic hyperthermia of melanoma mediated by iron(0)/iron oxide core/shell magnetic nanoparticles: a mouse study.
    Balivada S; Rachakatla RS; Wang H; Samarakoon TN; Dani RK; Pyle M; Kroh FO; Walker B; Leaym X; Koper OB; Tamura M; Chikan V; Bossmann SH; Troyer DL
    BMC Cancer; 2010 Mar; 10():119. PubMed ID: 20350328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia.
    Ito A; Kuga Y; Honda H; Kikkawa H; Horiuchi A; Watanabe Y; Kobayashi T
    Cancer Lett; 2004 Aug; 212(2):167-75. PubMed ID: 15279897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of intratumor magnetic nanoparticle distribution and heating in a rat model of metastatic spine disease.
    Zadnik PL; Molina CA; Sarabia-Estrada R; Groves ML; Wabler M; Mihalic J; McCarthy EF; Gokaslan ZL; Ivkov R; Sciubba D
    J Neurosurg Spine; 2014 Jun; 20(6):740-50. PubMed ID: 24702509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimelanoma effect of 4-S-cysteaminylcatechol, an activated form of 4-S-cysteaminylphenol.
    Inoue S; Hasegawa K; Ito S; Ozeki H; Solano F; Jiménez-Cervantes C; Wakamatsu K; Fujita K
    Cancer Res; 1995 Jun; 55(12):2603-7. PubMed ID: 7780975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer hyperthermia using magnetic nanoparticles.
    Kobayashi T
    Biotechnol J; 2011 Nov; 6(11):1342-7. PubMed ID: 22069094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.